Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 99 clinical trials
Featured trial
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration- CEDAR STUDY

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration- CEDAR STUDY

  • 1138 views
  • 23 Nov, 2020
  • 1 location
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (AVONELLE-X)

This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intravitreal injection at a personalized treatment interval to participants with neovascular age-related macular degeneration who enrolled in and completed one of the Phase III studies: GR40306 (NCT03823287) or …

  • 0 views
  • 30 Apr, 2022
  • 33 locations
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab (PDS) 100 mg/mL delivered every 36 weeks (Q36W) compared with every 24 weeks (Q24W) in patients with neovascular age-related macular degeneration (nAMD).

  • 0 views
  • 03 May, 2022
  • 51 locations
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (ShORe)

A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

  • 10 views
  • 12 May, 2022
  • 99 locations
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) (COAST)

A 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

  • 28 views
  • 14 May, 2022
  • 90 locations
Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration (Mylight)

Purpose and rationale: To demonstrate similar efficacy, safety and immunogenicity of SOK583A1 and Eylea EU as per Eylea approved treatment regimen in patients with nAMD. The primary clinical question of interest is: Does SOK583A1 have similar efficacy as Eylea EU in terms of mean change in BCVA score in participants …

  • 139 views
  • 02 May, 2022
  • 105 locations
Corneal Crosslinking for Treatment of Corneal Neovascularization

The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.

  • 0 views
  • 08 Sep, 2021
  • 1 location
Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization

Choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV) is a common vision-threatening complication and often affects adults of working age. Intravitreal injection of any anti

  • 0 views
  • 25 Mar, 2022
  • 1 location
Treat-and-extend Using Aflibercept for Type 3 Neovascularization

Type 3 neovascularization is a subtype of neovascular age-related macular degeneration (AMD) that is characterized by intraretinal neovascularization. Treat-and-extend (TAE) regimen is a widely

  • 0 views
  • 04 Mar, 2021
  • 1 location
601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)

To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to pmCNV

  • 0 views
  • 23 Jun, 2021
  • 1 location